Alongside the approval of Ponlimsi, the FDA is reviewing a BLA for TEV-45779, a biosimilar candidate for Xolair, covering all currently approved indications.

Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

The AHA says its recommended nutrition guidelines are rooted in research that links plant-based diets to a lower risk of ...

Researchers sought to examine sex-related differences in the association between depression subtypes and CVD risk in veterans ...

Quality of life outcomes were examined based on the presence and severity of hand eczema among patients with atopic dermatitis.

HealthDay News — The U.S. Centers for Disease Control and Prevention (CDC) has paused more than two dozen types of lab tests. Officials said the move is temporary. The explanation?

More than tripled risk of five-year mortality seen with use of complementary and alternative medicine alone compared with traditional therapies.

A significant percentage of older adults had improvements in chronic pain with medical cannabis use at 12 and 24 months.

It is estimated that 0.33% and 6.3% of total annual cardiovascular deaths were due to heat and cold, respectively.

Improvement in QoL, other PROs seen for those who switched to tirzepatide after not achieving glycemic control on stable dose of dulaglutide.

In this study, researchers aimed to characterize the relationship between major depressive disorder, use of antidepressants, and risk of recurrence in breast cancer patients.